New exit: Aparito sale to US pharma company is fourth exit this year for Wealth Club investors

A large US pharmaceutical company has just acquired clinical trials platform Atom5™ developed by Aparito Ltd – marking the fourth exit this year for Wealth Club single-company investors.

Wealth Club investors first invested in Aparito in 2019 and the sale in May 2024 provides early investors with returns of up to 3x.

Past performance is not a guide to the future. Investing in a single company without diversification is risky. You should expect some to fail. 

Important: The information on this website is for experienced investors. It is not advice nor a research or personal recommendation to invest. If you’re unsure, please seek advice. Investments are for the long term. They are high risk and illiquid and can fall as well as rise in value: you could lose all the money you invest.

More about Aparito

New drugs are notoriously expensive to develop – each typically costing over $2 billion and up to 15 years to bring to market. 

Wrexham-based Aparito has developed the Atom5™ software platform and app that efficiently addresses several problems that traditionally plague clinical trials – namely poor patient experience leading to high patient drop-out rates, patchy data, and escalating time-and-costs to completion. 

Patients input their own data in the app – such as medication times and dosage, and how they feel and function. Clinicians can see and speak to the patient via secure video conference, and the platform can conduct a wide range of reporting and data analysis. The technology can also generate real-time warnings if it suspects adverse events or an unexpected deterioration in the patient. 

Aparito’s Atom5™ platform technology already supports clinical trials in 18 languages across more than 20 countries. 


About the investment

Since 2019, Wealth Club investors invested a total of £1.4 million in Aparito under EIS.

At the point of Weath Club’s first investment, Aparito had built the technology and started to generate revenue. It had also been selected by Bayer AG – one of the world’s largest pharmaceutical companies – for its Accelerator program.

The majority of Wealth Club investors invested in 2019, with some following on in successive rounds. 

Valuation history of Aparito Ltd:

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.